Chengdu Olymvax Biopharmaceuticals Inc. A688319
▼ NegativeCapitalrelevance
Shareholder pledges 15.45% of its holdings, raising pledge ratio to 74.96%, signaling financial strain.

Olin Bio shareholder Taichang Group has pledged 4 million shares it holds, accounting for 15.45% of its holdings and 0.99% of the company's total share capital. As of the announcement date, Taichang Group has cumulatively pledged 19.41 million shares, representing 74.96% of its total holdings and 4.79% of the company's total share capital. In the first quarter of 2026, Olin Bio achieved revenue of 158 million yuan and net profit attributable to the parent company of 27.19 million yuan.
Chengdu Olymvax Biopharmaceuticals Inc. AShareholder pledges 15.45% of its holdings, raising pledge ratio to 74.96%, signaling financial strain.
Taichang Group pledges additional shares, increasing its cumulative pledge ratio to 74.96%.